AP24534(Ponatinib)

AP24534(Ponatinib)

AP24534(Ponatinib) CAS: 943319-70-8 /Email:phoebe@chembj.com

Product Name: AP24534(Ponatinib)

Synonyms: AP24534(Ponatinib);3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;AP24534;Ponatinib;3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide;Ponatinib (AP24534);Ponatinib (with 4 ints.);3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide

CAS: 943319-70-8

MF: C29H27F3N6O

MW: 532.22

Product Categories: Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Tyrosine Kinase Inhibitors;Potent multi-kinase and pan-BCR-ABL inhibitor.

Chemical Properties Pale Yellow Solid

Usage AP24534 is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN.

Usage Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor. Ponatinib inhibits both native and mutant BCR-ABL. Ponatinib is used in the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors.

Usage Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively

Note:

If you are intersted in our products, please contact us !

Email:phoebe@chembj.com

Skype:+8618827344661

Phone(whatsapp):+8618827344661